Ryan et al. [37] studied the adaptive response of KRAS G12C-mutant lung, colon, and pancreatic cancer cells to selective KRAS G12C inhibition using the covalent KRAS G12C inhibitors ARS-1620 and AMG 510. Here, KRAS is linked to pancreatic neoplasm.